Gene Transfer Therapy by Either Type 1 or Type 2 Adeno-Associated Virus Expressing Human Prostaglandin I 2 Synthase Gene is Effective for Treatment of Pulmonary Arterial Hypertension

Abstract

Prostaglandin I₂ (PGI₂) plays an important role in the clinical treatment of pulmonary arterial hypertension (PAH). However, the administration of PGI₂ involves continuous intravenous infusion using an indwelling catheter, which limits the patient’s quality of life and increases the risk of infection. We therefore investigated whether human PGI₂ synthase (hPGIS) gene transfer using an adeno-associated virus (AAV) vector is still effective in a mouse model of PAH and tested for differences in the therapeutic efficacy of PAH among AAV serotypes. The PAH was induced by subjecting mice to hypoxia (10% O₂). Type 1 AAV expressing hPGIS (AAV1-hPGIS) or type 2 AAV expressing hPGIS (AAV2-hPGIS) was injected into the thigh muscle of mice. Both vectors expressing hPGIS produced strong hPGIS protein expression in the mouse thigh skeletal muscles after 8 weeks of hypoxia. The administration of AAV1-hPGIS or AAV2-hPGIS also significantly inhibited the hypoxia-induced increase in right ventricular systolic pressure, the ratio of right ventricular weight to body weight (RV/BW), and the ratio of RV weight to left ventricular plus septal weight (RV/LV + S), and significantly attenuated the hypoxia-induced increase in medial wall thickness of peripheral pulmonary arteries. Furthermore, there were no significant differences in the degree of amelioration in RV systolic pressure, RV/BW, RV/LV + S, and percentage of wall thickness of peripheral pulmonary arteries between AAV1-hPGIS and AAV2-hPGIS administrations. In conclusion, we revealed that type 1 and type 2 AAV are equally effective for the treatment of PAH in a hypoxia-induced mouse model. Gene-transfer therapy using AAV expressing hPGIS is, therefore, a potential therapeutic breakthrough for PAH.

Keywords

pulmonary arterial hypertension adeno-associated virus gene transfer

Introduction

Pulmonary arterial hypertension (PAH) is a rare but life-threatening disease characterized by progressive pulmonary hypertension and right heart failure.¹ A study in 1991 of patients with idiopathic PAH² reported a median survival period of 2.8 years and 5-year survival rate of 34%. The pathogenesis of PAH includes pulmonary vasoconstriction, endothelial cell proliferation, smooth muscle cell proliferation, and in situ thrombosis.^3,4 Prostacyclin is a metabolite of arachidonic acid that has vasoprotective effects including vasodilation, antiplatelet aggregation, and inhibition of smooth muscle cell proliferation.^5

–8 Thus, continuous intravenous infusion of prostaglandin I₂ (PGI₂, prostacyclin) represented a therapeutic breakthrough for PAH.^9

–16 However, the duration of PGI₂ activity is so short that patients with PAH require continuous infusion through an indwelling central venous catheter and this eventually limits the patients’ quality of life.^17

–20 Furthermore, there is a risk of catheter infection, which could exacerbate right heart failure.

Previously, we demonstrated that human PGI₂ synthase (hPGIS) gene transfer using adeno-associated virus (AAV) vector is an effective treatment of PAH in mice.²¹ Among the various virus vectors, AAV is known to be safe and has already been used in humans for the treatment of hemophilia, cystic fibrosis, and Parkinson disease.^22
–24 Gene therapy for hPGIS could, therefore, be a potent method for treating PAH. Gene therapy with hPGIS using AAV in clinical settings may not require the indwelling catheter, resulting in an improved quality of life for the patient and the avoidance of catheter infection.

There are several AAV serotypes, of which type 2 AAV (AAV2) is the most common one used in AAV-based research and in clinical settings for humans.^22
–24 We also demonstrated the efficacy of hPGIS gene transfer using AAV for the treatment of PAH, although we used type 1 AAV (AAV1) because it provides very high transduction rates in murine skeletal muscle cells and our study involved the intramuscular injection of AAV into the thigh muscle of mice.²¹ Thus, it is important to compare treatment efficiency between AAV1 and AAV2 for the potential clinical application of AAV-based therapy.

Therefore, the purposes of this study were (1) to investigate whether PGIS gene transfer therapy using not only AAV1 but also AAV2 is effective for the treatment of mice with PAH and (2) to compare the treatment efficiency between AAV1 and AAV2.

Methods and Materials

AAV Vectors

The AAV vectors expressing hPGIS were constructed in good laboratory practice by Dynavec Corporation (Ibaragi, Japan).

Animal Experiments

Eight-week-old male C57/BL6 mice purchased from Japan CLEA (Tokyo, Japan) were used in this study. To generate PAH model, mice were kept in a tightly sealed chamber under hypoxia (10% O₂) for 8 weeks, maintained using a hypoxic air generator (TEIJIN, Tokyo, Japan) and monitored with an O₂ analyzer (JIKO-255, Tokyo, Japan). All experimental procedures and protocols were approved by the Animal Care and Use Committees of Keio University.

We randomly divided mice into 4 groups and assigned mice to 1 additional control group for comparison, mice injected with 0.9% saline (vehicle) under room air (control group, n = 10), PAH mice exposed to hypoxia and injected with AAV1 expressing enhanced green fluorescent protein ([EFGP] AAV1-EGFP group, n = 8), PAH mice exposed to hypoxia and injected with AAV2 expressing EFGP (AAV2-EGFP group, n = 8), PAH mice exposed to hypoxia and treated with AAV1 expressing hPGIS (AAV1-hPGIS group, n = 10), and PAH mice exposed to hypoxia and treated with AAV2 expressing hPGIS (AAV2-hPGIS group, n = 10) (Table 1).

Table 1.

Physiological Profiles of 5 Experimental Groups^a

Parameter	Control	AAV1-EGFP	AAV2-EGFP	AAV1-hPGIS	AAV2-hPGIS
n	10	8	8	10	10
Body weight, g	25.5 ± 1.9	20.4 ± 0.9^b	20.9 ± 1.0^b	22.6 ± 0.6^b,c,d	22.5 ± 1.9^b,c,d
RV systolic pressure, mm Hg	19 ± 1	52 ± 6^b	48 ± 15^b	34 ± 5^b,c,d	32 ± 3^b,c,d
RV/BW, g/kg body weight	0.64 ± 0.15	1.25 ± 0.17^b	1.36 ± 0.23^b	0.90 ± 0.16^b,c,d	0.87 ± 0.15^b,c,d
RV/LV + S	0.20 ± 0.03	0.39 ± 0.05^b	0.43 ± 0.10^b	0.32 ± 0.05^b,c,d	0.30 ± 0.04^b,c,d

Abbreviations: AAV, adeno-associated virus; BW, body weight; LV, left ventricle; RV, right ventricle.

^aThese measurements were performed 8 weeks after the injection of vehicle or adeno-associated virus (AAV). Control group, mice given vehicle and placed under room air; AAV1-EGFP group, mice given type 1 AAV expressing enhanced green fluorescent protein (EGFP) and placed under hypoxia; AAV2-EGFP group, mice given type 2 AAV expressing EGFP and placed under hypoxia; AAV1-hPGIS group, mice given type 1 AAV expressing human prostaglandin I₂ synthase (hPGIS); AAV2-hPGIS group, mice given type 2 AAV expressing hPGIS; RV, right ventricular; RV/BW, ratio of RV weight to body weight; RV/LV + S, ratio of RV weight to left ventricular plus septal weight. Data are expressed as mean ± standard deviation.

^b P < .05 versus control.

^b P < .05 versus AAV1-EGFP group.

^c P < .05 versus AAV2-EGFP group.

Experimental Protocols

After 24 hours of exposure to hypoxia, AAV1-EGFP, AAV2-EGFP, AAV1-hPGIS, or AAV2-hPGIS (1.0 × 10¹⁰ vector genome/body) was administered into the right thigh muscle of mice by single injection. The vehicle (0.9% saline) was injected into the same site in the control group. Hemodynamics was measured at 8 weeks. To do this, light anesthesia with diethyl ether was administered. The mice were then intubated, mechanically ventilated with a Harvard respirator, and anesthetized with isoflurane. Left thoracotomy was performed and a 1.4-F microtip pressure transducer (SPR-671; Millar Instruments, Houston, Texas) was directly inserted into the right ventricle (RV), and the RV pressure was recorded using a polygraph system (Nihon Kohden, Tokyo, Japan). After hemodynamic measurements, the RV, left ventricle (LV), ventricular septum, lungs, and right thigh muscle were excised, weighed, and retained for further analysis. The ratio of RV weight to body weight (RV/BW) and the ratio of RV weight to LV plus septal weight (RV/LV + S) were calculated as indexes of ventricular hypertrophy.

Histological Analysis

Paraffin sections of 4-μm thickness were obtained from the middle region of the right lung and stained with elastic van Gieson for examination by light microscopy. The external diameter and medial wall thickness of the pulmonary arterioles were measured in 20 muscular arteries (ranging in size from 25 to 100 μm in external diameter). The medial wall thickness was expressed as follows: % wall thickness = ([medial thickness × 2]/external diameter) × 100. A lung section was obtained from individual mice in 5 groups (n = 5 each), as reported previously.²⁵ In addition, thigh muscle sections were stained with anti-human PGIS antibody, as described previously.⁷ The percentage area of hPGIS staining in immunostaining images (original magnification × 200) was calculated using Image J software (n = 5 each).

Statistical Analysis

All data were expressed as mean ± standard deviation. Comparisons of parameters among the groups were made by 1-way analysis of variance, followed by Newman-Keul test. A value of P < .05 was considered statistically significant.

Results

The AAV-Mediated hPGIS Gene Expression In Vivo

There were no mice that died during the experiment. We performed immunofluorescent staining for hPGIS in histological sections of right thigh skeletal muscles from the AAV-injected mice. The mice administered with AAV1-hPGIS or AAV2-hPGIS showed strong hPGIS protein expression in their thigh skeletal muscles, while no signal was found in mice administered with AAV1-EGFP or AAV2-EGFP (Figure 1A). Furthermore, to compare the transduction rate of hPGIS gene, the percentage area of PGIS protein expression was calculated (Figure 1B). The PGIS protein expressions were significantly higher in mice administered with AAV1-hPGIS or AAV2-hPGIS than in mice administered with AAV1-EGFP or AAV2-EGFP. There was no significant difference in the PGIS expression between mice administered with AAV1-hPGIS and those with AAV2-hPGIS.

There was no evidence of tumor or angioma formation in muscle from any of the mice transferred with AAV1-EGFP, AAV2-EGFP, AAV1-hPGIS, or AAV2-hPGIS. Furthermore, there were no findings of inflammatory cell infiltrate and interstitial edema to suggest inflammation induced by AAV injection in any of the AAV-injected mice.

Effects of AAV-hPGIS on Pulmonary Hemodynamics and Right Ventricular Hypertrophy

Right ventricular systolic pressure was significantly increased after 8 weeks of sustained hypoxia in the AAV1-EGFP and AAV2-EGFP groups (Figure 2A). However, the increase was significantly attenuated in both the AAV1-hPGIS and AAV2-hPGIS groups. Similarly, the increase in RV/BW in the AAV1-EGFP and AAV2-EGFP groups was significantly attenuated in the AAV1-hPGIS and AAV2-hPGIS groups (Figure 2B), and the same was found for the hypoxia-induced increase in RV/LV + S (Figure 2C). There were no significant differences between the AAV1-hPGIS group and the AAV2-hPGIS group in RV systolic pressure, RV/BW, or RV/LV + S.

Effects of AAV-hPGIS on Vascular Remodeling

Representative photomicrographs show attenuated hypertrophy of the pulmonary vessel wall after sustained hypoxia in both the AAV1-hPGIS and AAV2-hPGIS groups compared with the AAV1-EGFP and AAV2-EGFP groups (Figure 3A). The demonstrated significant increase in percentage of wall thickness after sustained hypoxia in the AAV1-EGFP and AAV2-EGFP groups was also ameliorated in both the AAV1-hPGIS and AAV2-hPGIS groups (Figure 3B). The degree of amelioration in percentage of wall thickness was not significantly different between the AAV1-hPGIS group and the AAV2-hPGIS group.

Discussion

In the present study, we demonstrated that (1) hPGIS is expressed in the thigh muscles of mice after a single injection of AAV-hPGIS; (2) a single injection of AAV1-hPGIS or AAV2-hPGIS ameliorated hypoxia-induced PAH; and (3) the efficacy of treatment for PAH was not significantly different between AAV1 and AAV2 administrations.

In recent years, AAV vectors have received wide attention because they are nonpathogenic and nontoxic in humans and show long-term gene expression in nondividing cells, confirming their strong efficacy, and safety for human use. In the present study, the strong gene expression of hPGIS in skeletal muscle 8 weeks after the injection of AAV-hPGIS (both AAV1-hPGIS and AAV2-hPGIS) demonstrated that a single injection is sufficient to achieve high efficiency of gene transfer in vivo. The present study also demonstrated that a single administration of AAV-hPGIS could markedly attenuate the development of hypoxia-induced PAH, as indicated by significant decreases in RV systolic pressure and RV weight. Furthermore, AAV-hPGIS also attenuated the increase in medial wall thickness of peripheral pulmonary arteries observed in PAH, thus administration of AAV-hPGIS offers an alternative approach to epoprostenol for treating severe PAH.

This study was also designed to directly compare the efficacy of AAV1-hPGIS and AAV2-hPGIS in a mouse model of PAH, considering that both AAV1 and AAV2 have documented benefits for potential therapeutic use in humans.^22
–24 Our results revealed long-lasting efficiency of gene expression in thigh muscles administered with either serotype and there was no significant difference in the PGIS protein expression between AAV1 and AAV2 vectors. Hemodynamics, RV weight, and medial wall thickness of peripheral pulmonary arteries were not significantly different between AAV1 and AAV2 vectors. These findings suggest that the efficacy of treatment for PAH would be similar between AAV1 and AAV2, although AAV2-hPGIS has the advantage that AAV2 has already been used safely in the human clinical setting. Thus, these findings suggest that AAV2 may be appropriate to use when the gene transfer therapy using AAV is applied for the treatment of PAH in the human clinical setting.

There are several study limitations in this study. The AAV-hPGIS was administered 24 hours after the exposure to hypoxia. Thus, our findings suggest that AAV-hPGIS significantly inhibited the development of PAH. However, the effects of AAV-hPGIS on the advanced PAH are still unclear. Furthermore, hemodynamics and histological analysis were performed at 8 weeks after the administration of AAV-hPGIS. In addition, there is a possibility that the antibody against AAV is formed during the long-term treatment period and diminishes the efficacy of AAV-hPGIS. Thus, the analysis of further long-term therapeutic effects of AAV-hPGIS including the detection of the antibody against AAV should be investigated in future studies. Moreover, more detailed analyses regarding the differences of AAV1-hPGIS and AAV2-hPGIS such as systemic blood pressure, expression of PGIS messenger RNA, PGI₂ metabolites, and production of neutralizing antibody are desirable. For clinical use, further studies, such as acute and chronic toxicology analyses, central nervous system function testing, cardiovascular and respiratory safety pharmacology studies, sterility testing, and endotoxin tests are also necessary.

Conclusion

The present study revealed that type 1 and type 2 AAV are equally effective in the treatment of PAH, indicating that gene transfer therapy using AAV vectors expressing hPGIS represent a novel therapeutic strategy for PAH.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported in part by the Health and Labour Sciences Research Grant from the Ministry of Health, Labour, and Welfare of Japan, and by the Grant from Actelion Academia Prize 2010.

References

Rich

Dantzker

Ayres

. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–223.

D’Alonzo

Barst

Ayres

. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.

Rich

Clinical insights into the pathogenesis of primary pulmonary hypertension. Chest. 1998;114(3 suppl):237S–241S.

Archer

Rich

. Primary pulmonary hypertension: a vascular biology and translational research “work in progress.” Circulation. 2000;102(22):2781–2791.

Moncada

Gryglewski

Bunting

Vane

. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263(5579):663–665.

Moncada

Vane

. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300(20):1142–1147.

Nagaya

Yokoyama

Kyotani

. Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation. 2000;102(16):2005–2010.

Rich

McLaughlin

. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999;34(4):1184–1187.

Higenbottam

Wheeldon

Wells

Wallwork

. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1(8385):1046–1047.

10.

Rubin

Mendoza

Hood

. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med. 1990;112(7):485–491.

11.

Higenbottam

Spiegelhalter

Scott

. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J. 1993;70(4):366–370.

12.

Barst

Rubin

McGoon

Caldwell

Long

Levy

. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121(6):409–415.

13.

Barst

Rubin

Long

. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–302.

14.

McLaughlin

Genthner

Panella

Rich

. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338(5):273–277.

15.

McLaughlin

Shillington

Rich

. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482.

16.

Sitbon

Humbert

Nunes

. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–788.

17.

Okano

Yoshioka

Shimouchi

Satoh

Kunieda

. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet. 1997;349(9062):1365.

18.

Nagaya

Uematsu

Okano

. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34(4):1188–1192.

19.

Olschewski

Simonneau

Galie

. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.

20.

Simonneau

Barst

Galie

. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–804.

21.

Kawakami

Kanazawa

Satoh

. AAV-PGIS gene transfer improves hypoxia-induced pulmonary hypertension in mice. Biochem Biophys Res Commun. 2007;363(3):656–661.

22.

Manno

Pierce

Arruda

. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–347.

23.

Wagner

Reynolds

Moran

. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 1998;351(9117):1702–1703.

24.

During

Kaplitt

Stern

Eidelberg

. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther. 2001;12(12):1589–1591.

25.

Kataoka

Nagaya

Satoh

. A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1575–1580.